Pfizer will end development of daily weight-loss pill after liver injury

Pfizer announced on Monday that it is halting development of its oral weight-loss pill after one patient experienced liver issues. 

The company said it halted development of danuglipron, an oral drug being investigated for chronic weight management, after discovering that a "participant in one of the dose-optimization studies experienced potential drug-induced liver injury," which was resolved after the patient stopped using the drug. 

Among the over 1,400 people who took the drug...